Expertise in
9
conditions

Dr. Neal Flomenberg

Hematology | Oncology
Office
925 Chestnut St Ste 420A, 
Philadelphia, PA 
43 Years of Experience
Expertise in
9
conditions
Office
925 Chestnut St Ste 420A, 
Philadelphia, PA 

Overview

Neal Flomenberg is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. He has been practicing medicine for over 43 years.

Dr. Flomenberg is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Myeloblastic Leukemia without Maturation, Graft Versus Host Disease (GvHD), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 42 peer reviewed articles and participating in 13 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in PA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Office
925 Chestnut St Ste 420A, Philadelphia, PA 19107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: May 29, 2026
Intervention Type: Drug
Study Drugs: Sirolimus, Mitoxantrone, Etoposide, Cytarabine
Study Phase: Phase 2
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: April 15, 2026
Intervention Type: Radiation, Drug, Biological, Device, Procedure
Study Drugs: Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Donor Lymphocyte Infusion
Study Phase: Phase 2
A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies
A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies
Enrollment Status: Completed
Publish Date: March 19, 2026
Intervention Type: Device
Study Phase: Phase 2
A Randomized Controlled Trial Evaluating the Use of G-CSF After Plerixafor-Mobilized Autologous Stem Cell Transplant (Auto HSCT)
A Randomized Controlled Trial Evaluating the Use of G-CSF After Plerixafor-Mobilized Autologous Stem Cell Transplant (Auto HSCT)
Enrollment Status: Completed
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Drug
Study Drug: Tbo-Filgrastim
Study Phase: Phase 2
Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Enrollment Status: Completed
Publish Date: December 15, 2025
Intervention Type: Drug, Radiation, Genetic
Study Phase: Phase 2
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
Enrollment Status: Completed
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: Sirolimus, Azacitidine
Study Phase: Phase 2
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies
Enrollment Status: Completed
Publish Date: October 30, 2025
Intervention Type: Drug, Radiation, Procedure, Other, Biological
Study Drugs: Fludarabine, Thiotepa, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Allogeneic Lymphocytes
Study Phase: Phase 2
A 2 Step Approach to Matched Related Hematopoietic Stem Cell Transplantation for Patients With Hematological Malignancies-5+5 Dosing
A 2 Step Approach to Matched Related Hematopoietic Stem Cell Transplantation for Patients With Hematological Malignancies-5+5 Dosing
Enrollment Status: Completed
Publish Date: August 22, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Phase 2
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
Enrollment Status: Withdrawn
Publish Date: May 02, 2025
Intervention Type: Drug, Radiation, Biological, Procedure
Study Phase: Phase 1
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug, Biological, Procedure, Radiation
Study Phase: Phase 2
View 9 Less Clinical Trials

42 Total Publications

The Two-Step Allogeneic Stem Cell Transplant Is Associated with Excellent Engraftment, Improved Survival and Low Nonrelapse Mortality in Patients with Myelofibrosis.
The Two-Step Allogeneic Stem Cell Transplant Is Associated with Excellent Engraftment, Improved Survival and Low Nonrelapse Mortality in Patients with Myelofibrosis.
Journal: Hematology/oncology and stem cell therapy
Published: September 03, 2025
Similar Doctors
Expertise in
14
conditions
Dr. Janet Kwiatkowski
Hematology | Oncology
Expertise in
14
conditions
Dr. Janet Kwiatkowski
Hematology | Oncology
Referral may be required

Office

3401 Civic Center Blvd, 
Philadelphia, PA 
 (2.0 miles away)
215-590-1000
Languages Spoken:
English
See accepted insurances

Janet Kwiatkowski is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Kwiatkowski is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Hemolytic Anemia, Congenital Hemolytic Anemia, Anemia, Bone Marrow Transplant, and Splenectomy.

Expertise in
18
conditions
Dr. Daniel Geynisman
Hematology | Oncology
Expertise in
18
conditions
Dr. Daniel Geynisman
Hematology | Oncology
Referral may be required

Fox Chase Cancer Center

333 Cottman Ave, 
Philadelphia, PA 
 (9.0 miles away)
215-728-6900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Geynisman is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Geynisman is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Orchiectomy.

Expertise in
10
conditions
Dr. John Maris
Hematology | Oncology
Expertise in
10
conditions
Dr. John Maris
Hematology | Oncology
Referral may be required

Office

3401 Civic Center Blvd, 
Philadelphia, PA 
 (2.0 miles away)
215-590-1000
Languages Spoken:
English

John Maris is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Maris is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Rhabdomyosarcoma, Hereditary Neuroblastoma, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Neal Flomenberg

How do I make an appointment with Dr. Neal Flomenberg?

You can book an appointment with Dr. Neal Flomenberg by calling their office at 215-955-8874. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Neal Flomenberg a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Neal Flomenberg is classified as an Distinguished expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Neal Flomenberg specialize in?

While Dr. Neal Flomenberg is a Hematology, they have specific expertise in Bone Marrow Transplant, Acute Myeloid Leukemia (AML), and Myelodysplastic Syndrome (MDS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Neal Flomenberg participate in research or clinical trials?

Yes. Dr. Neal Flomenberg has published 42 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Dr. Neal Flomenberg's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Neal Flomenberg accept my insurance?

Dr. Neal Flomenberg accepts most major insurance plans, including Cigna and Humana. We recommend calling the office directly at 215-955-8874 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Flomenberg's expertise for a condition
ConditionClose
    View All 27 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile